How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease

Hayato Fujioka; Naoya Kataoka; Teruhiko Imamura

doi:10.2169/internalmedicine.2725-23

How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease

Hayato Fujioka, Naoya Kataoka, Teruhiko Imamura^*

^*この論文の責任著者

内科学（第二）講座

研究成果: ジャーナルへの寄稿 › Letter › 査読

本文言語	英語
ページ（範囲）	2227
ページ数	1
ジャーナル	Internal Medicine
巻	63
号	15
DOI	https://doi.org/10.2169/internalmedicine.2725-23
出版ステータス	出版済み - 2024

ASJC Scopus 主題領域

内科学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.2169/internalmedicine.2725-23

引用スタイル

@article{d08a1c44f84a42fc987c64843dd0bb9e,

title = "How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease",

keywords = "cardiovascular disease, heart failure, SGLT2 inhibitor, uric acid",

author = "Hayato Fujioka and Naoya Kataoka and Teruhiko Imamura",

year = "2024",

doi = "10.2169/internalmedicine.2725-23",

language = "英語",

volume = "63",

pages = "2227",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "15",

}

TY - JOUR

T1 - How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease

AU - Fujioka, Hayato

AU - Kataoka, Naoya

AU - Imamura, Teruhiko

PY - 2024

Y1 - 2024

KW - cardiovascular disease

KW - heart failure

KW - SGLT2 inhibitor

KW - uric acid

UR - http://www.scopus.com/inward/record.url?scp=85200161927&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.2725-23

DO - 10.2169/internalmedicine.2725-23

M3 - Letter

C2 - 38171852

AN - SCOPUS:85200161927

SN - 0918-2918

VL - 63

SP - 2227

JO - Internal Medicine

JF - Internal Medicine

IS - 15

ER -